| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Lumexa Imaging Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| Fr | Welsh Carson scores IPO exit as Lumexa Imaging raises $463m in US debut | 3 | Private Equity Insights | ||
| Fr | Lumexa Imaging raises $463m in IPO | 1 | Private Equity Wire | ||
| Fr | Lumexa Imaging Holdings, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| Do | Moody's stuft Lumexa Imaging nach erfolgreichem Börsengang auf B2 hoch | 3 | Investing.com Deutsch | ||
| Do | Lumexa Imaging valued at $1.76 billion as shares edge up in Nasdaq debut | 2 | Reuters | ||
| Do | Lumexa Imaging prices IPO at $18.50, within the range | 1 | Renaissance Capital | ||
| Do | Lumexa Imaging Holdings, Inc. - 8-A12B, Registration of securities | - | SEC Filings | ||
| LUMEXA IMAGING Aktie jetzt für 0€ handeln | |||||
| Do | Welsh Carson-backed Lumexa Imaging raises $463 million in US IPO | 2 | Reuters | ||
| Do | Lumexa Imaging prices IPO at $18.50 per share, to list on Nasdaq | 4 | Investing.com | ||
| Do | Lumexa Imaging Announces Pricing of Initial Public Offering | 77 | PR Newswire | RALEIGH, N.C., Dec. 10, 2025 /PRNewswire/ -- Lumexa Imaging Holdings, Inc. ("Lumexa Imaging") announced today the pricing of its initial public offering of 25,000... ► Artikel lesen | |
| 02.12. | Welsh Carson-backed Lumexa targets $1.89bn valuation in US IPO as PE pipeline reopens | 2 | Private Equity Insights | ||
| 02.12. | Outpatient radiology network Lumexa Imaging sets terms for $463 million IPO | 1 | Renaissance Capital | ||
| 02.12. | Lumexa Imaging Holdings, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 18.11. | Diagnostic imaging provider Lumexa Imaging Holdings files for an estimated $200 million IPO | 1 | Renaissance Capital | ||
| 17.11. | Lumexa Imaging files for US IPO | 2 | Reuters | ||
| 17.11. | Lumexa Imaging Holdings, Inc. - S-1, General form for registration of securities | - | SEC Filings |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SIEMENS HEALTHINEERS | 44,030 | +0,94 % | Starke Kursanstiege - AJN Resources, Delivery Hero, Siemens Healthineers | Ein massiver Stellenabbau betrifft nicht nur die deutsche Wirtschaft, auch in der Schweiz sind Umstrukturierungen erforderlich, um sich den Marktgegebenheiten anzupassen. Nach der überstürzten Übernahme... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,130 | +0,53 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| FRESENIUS | 47,560 | -0,73 % | AKTIEN IM FOKUS: Medizintechnikwerte von Exane bewegt - 'Zweigeteiltes 2026' | FRANKFURT (dpa-AFX) - Die Aktien von Siemens Healthineers und Sartorius haben am Mittwoch nach einer Studie von Exane BNP Paribas zum europäischen Medizintechniksektor unterschiedliche Richtungen eingeschlagen.... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 19,360 | -0,31 % | Alignment Healthcare Reports Third Quarter 2025 Results, Surpasses High-End of Guidance Across All Key Metrics | Reports Q3 revenue of $993.7 million, up 43.5% year-over-yearBeats high end of third quarter guidance and raises full-year outlook across all key metrics: membership, revenue, adjusted gross profit... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 40,580 | +1,45 % | EQS-Adhoc: Carl Zeiss Meditec AG: Beendigung der Vorstandstätigkeit von Maximilian Foerst zum 31.12.2025 und interimistische Übernahme des Vorstandsvorsitzes durch Andreas Pecher zum 01.01.2026 | EQS-Ad-hoc: Carl Zeiss Meditec AG / Schlagwort(e): Personalie
Carl Zeiss Meditec AG: Beendigung der Vorstandstätigkeit von Maximilian Foerst zum 31.12.2025 und interimistische Übernahme... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 35,990 | -0,11 % | UBS stuft Procept BioRobotics mit "Buy" ein - Wachstum bei Systemauslastung als Treiber | ||
| GERRESHEIMER | 28,040 | +6,62 % | Gerresheimer: Rückblick auf eine Trading-Idee! | ||
| BETA BIONICS | 29,760 | +1,54 % | Beta Bionics, Inc.: Beta Bionics to Pre-Announce Topline Fourth Quarter 2025 Financial Results the Week of January 5, 2026 | ||
| GENEDX | 151,32 | -2,61 % | GeneDx and Guardant Health named as BTIG's top picks for 2026 | ||
| BRIGHTSPRING HEALTH SERVICES | 36,540 | +1,78 % | BrightSpring upgraded at KeyBanc on specialty pharmacy and EBITDA prospects | ||
| CASTLE BIOSCIENCES | 38,630 | +1,68 % | Castle Biosciences, Inc.: Systematic Review and Meta-Analysis Confirms TissueCypher Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer | FRIENDSWOOD, Texas, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication... ► Artikel lesen | |
| PROGYNY | 26,720 | +2,73 % | Progyny, Inc. Announces Third Quarter 2025 Results | Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and... ► Artikel lesen | |
| HEARTBEAM | 2,300 | +7,98 % | Heartbeam stock is a buy, this analyst says | ||
| ADAPTHEALTH | 10,400 | +1,46 % | AdaptHealth: Strategische Expansion und Technologie-Investitionen als Wachstumstreiber | ||
| PACS GROUP | 34,800 | +4,35 % | Truist Securities hebt Kursziel für PACS Group auf 40 US-Dollar an |